Dr. Ramon Leon, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 241
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license ME0092409
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Hospital of Miami Miami, FL
- South Miami Hospital Miami, FL
- Doctors Hospital Coral Gables, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 241
- Services billed
- 1,330
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 466 | 153 |
| Insertion of needle into vein for collection of blood sample | 149 | 99 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 116 | 116 |
| Established patient office or other outpatient visit, 20-29 minutes | 94 | 61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 69 | 66 |
| Injection of drug or substance under skin or into muscle | 54 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 25 payments worth $611 in total to this clinician.
| Pfizer Inc. | $147 |
|---|---|
| Lilly USA, LLC | $119 |
| Astellas Pharma US Inc | $116 |
| Novo Nordisk Inc | $63.03 |
| Amgen Inc. | $39.92 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.07 |
| Sumitomo Pharma America, Inc. | $28.35 |
| Abbott Laboratories | $21.55 |
| Food and Beverage | $516 |
|---|---|
| Education | $94.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Mar 25, 2025 | Education in-kind | $94.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 11 companies. The companies reported $1,511,062 in research payments for these studies, mostly to the institutions running them.
- A phase 2, parallel group, randomized, double-blind, placebo-controlle
GlaxoSmithKline, LLC. - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06126224 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
AbbVie Inc. · Completed · NCT05291234 - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - A multi-center, single arm, open-label extension study to evaluate the
GlaxoSmithKline, LLC. - A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.